Please assess the completion status of the following clinical trial:

Trial Title: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must satisfy the following criteria to be enrolled in the study:~1. Subject is ≥ 18 years of age the time of signing the informed consent form (ICF).~2. Documented diagnosis of MDS according to World Health Organization (WHO)/French American British (FAB) classification that meets IPSS R classification of very low, low, or intermediate risk disease, and:~Ring sideroblast ≥ 15% of erythroid precursors in bone marrow or ≥ 5% (but \< 15%) if SF3B1 mutation is present.~* \< 5% blasts in bone marrow~* Peripheral blood white blood cell (WBC) count \< 13,000/µL 3. Requires red blood cell RBC transfusions 4. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 5. Subjects who are refractory/intolerant/ineligible to prior erythropoietin-stimulating agents (ESA) treatment, defined as:~* Refractory to prior - erythropoietin stimulating agents treatment: documentation of non-response or response that is no longer maintained to prior ESA-containing regimen, either as single agent or combination (eg, with granulocyte colony stimulating factor (G-CSF); ESA regimen must have been either recombinant human erythropoietin (rHu EPO) ≥ 40,000 IU/wk for at least 8 doses or equivalent OR darbepoetin alpha ≥ 500 μg Q3W for at least 4 doses or equivalent~* Intolerant to prior ESA treatment: documentation of discontinuation of prior ESA-containing regimen, either as single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an adverse event~* ESA ineligible: low chance of response to ESA base on endogenous serum erythropoietin level \> 200 U/L for subjects not previously treated with ESAs~Exclusion Criteria:~The presence of any of the following will exclude a subject from enrollment:~1. Prior therapy with disease modifying agents for underlying MDS disease.~2. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)~3. MDS associated with del 5q cytogenetic abnormality~4. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases.~5. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding~   - iron deficiency to be determined by serum ferritin less than or equal to 15 ug/L and additional testing if clinically indicated (eg, calculated transferrin saturation \[iron/total iron binding capacity less than or equal to 20%\] or bone marrow aspirate stain for iron).~6. Prior allogeneic or autologous stem cell transplant~7. Known history of diagnosis of acute myeloid leukemia (AML)~8. Use of any of the following within 5 weeks prior to randomization:~   * anticancer cytotoxic chemotherapeutic agent or treatment~  * corticosteroid, except for subjects on a stable or decreasing dose for ≥ 1 week prior to randomization for medical conditions other than MDS~  * iron-chelating agents, except for subjects on a stable or decreasing dose for at least 8 weeks prior to randomization~  * other RBC hematopoietic growth factors (eg, Interleukin-3)~  * investigational drug or device, or approved therapy for investigational use. If the half-life of the previous investigational product is known, use within 5 times the half-life prior to randomization or within 5 weeks, whichever is longer is excluded.~9. Prior history of malignancies, other than MDS, unless the subject has been free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for ≥ 5 years. However, subjects with the following history/concurrent conditions are allowed:~   * Basal or squamous cell carcinoma of the skin~  * Carcinoma in situ of the cervix~  * Carcinoma in situ of the breast~  * Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \[TNM\] clinical staging system)~10. Major surgery within 8 weeks prior to randomization. Subjects must have completely recovered from any previous surgery prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm - Luspatercept (ACE-536) (Type: EXPERIMENTAL): Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
- Control Arm: Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injection every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete